Reports
- 2023 ESG Report & Data Content Index
-
Samsung Biologics published the 2023 ESG Report, which covered the performance and plans related to ESG for the years 2022 and 2023. This report aims to disclose the impact of the company’s businesses and activities to address ESG-related issues on the society and environment to the shareholders in a transparent manner. Samsung Biologics will continue to publish the ESG Report annually to engage and move forward with stakeholders.
- Reporting Period
-
This report presents the company’s financial, social and environmental performance and activities during the period of January 1, 2022 - December 31, 2022. Some pieces of information from the first half of 2023 are included due to their significance. Data for the last three years from 2020 to 2022 (four years from 2019 to 2022 for some environmental data) was provided to measure the yearly changes in quantitative performance. For data published in Facts & Figures, we have revised data from previous years (2019-2021) for the following reasons:
Calculation scope/basis changes: Employee performance appraisal ratio, employee training, parental leave, Scope 3 GHG emissions Error correction: Waste (Incineration waste volume in 2019 and 2020, total waste generation and treatment volume in 2021, waste recycling volume in 2021) Unified standards for consolidated companies: employee diversity, new hires, and employee turnover
- Reporting Standards
-
This report aligns with the Global Reporting Initiative (GRI) Standards 2021, which are the standards for sustainability reporting. ISO 26000, the UN Global Compact Principles, the IR Framework, the SASB (Sustainability Accounting Standards Board), and the TCFD (Task Force on Climate-related Financial Disclosure) recommendations were referenced when writing the report.
- Reporting Scope
-
This report covers the ESG management activities and performance of all business sites in and outside of South Korea. Financial data is provided in the K-IFRS consolidated format, and non-financial data includes Samsung Biologics’ business sites in Korea and data from Samsung Bioepis, a subsidiary of the company. This report is for the fiscal year in line with the disclosure system of the company, and the energy consumption data and greenhouse gas emissions provided are based on the verification result.
2023 ESG Report & Data Content Index
Samsung Biologics published the 2023 ESG Report, which covered the performance and plans related to ESG for the years 2022 and 2023. This report aims to disclose the impact of the company’s businesses and activities to address ESG-related issues on the society and environment to the shareholders in a transparent manner. Samsung Biologics will continue to publish the ESG Report annually to engage and move forward with stakeholders.
- Reporting Period
-
This report presents the company’s financial, social and environmental performance and activities during the period of January 1, 2022 - December 31, 2022. Some pieces of information from the first half of 2023 are included due to their significance. Data for the last three years from 2020 to 2022 (four years from 2019 to 2022 for some environmental data) was provided to measure the yearly changes in quantitative performance. For data published in Facts & Figures, we have revised data from previous years (2019-2021) for the following reasons:
Calculation scope/basis changes: Employee performance appraisal ratio, employee training, parental leave, Scope 3 GHG emissions Error correction: Waste (Incineration waste volume in 2019 and 2020, total waste generation and treatment volume in 2021, waste recycling volume in 2021) Unified standards for consolidated companies: employee diversity, new hires, and employee turnover
- Reporting Standards
-
This report aligns with the Global Reporting Initiative (GRI) Standards 2021, which are the standards for sustainability reporting. ISO 26000, the UN Global Compact Principles, the IR Framework, the SASB (Sustainability Accounting Standards Board), and the TCFD (Task Force on Climate-related Financial Disclosure) recommendations were referenced when writing the report.
- Reporting Scope
-
This report covers the ESG management activities and performance of all business sites in and outside of South Korea. Financial data is provided in the K-IFRS consolidated format, and non-financial data includes Samsung Biologics’ business sites in Korea and data from Samsung Bioepis, a subsidiary of the company. This report is for the fiscal year in line with the disclosure system of the company, and the energy consumption data and greenhouse gas emissions provided are based on the verification result.